Role of serum albumin and proteinuria in patients with SARS-CoV-2 pneumonia.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
18
05
2020
accepted:
14
12
2020
pubmed:
18
12
2020
medline:
7
4
2021
entrez:
17
12
2020
Statut:
ppublish
Résumé
Hypoalbuminemia is frequently observed in patients with SARS-CoV-2 infection although its underlying mechanism and relationship with the clinical outcome still need to be clarified. We retrospectively evaluated in patients with COVID-19 hospitalised at the Fatebenefratelli-Sacco Hospital in Milan, the prevalence of hypoalbuminemia, its association with the severity of COVID-19, with the levels of C-reactive protein, d-dimer and interleukin-6 and with clinical outcome over a follow-up period of 30 days. Urinalysis was evaluated in a subgroup of patients. Serum albumin levels <30 g/L were found in 105/207 (50.7%) patients at hospital admission. Overall, the median albumin value was 29.5 g/L (IQR 25-32.8). A negative association was found between albumin levels and severity of COVID-19 (P < .0001) and death (P = .003). An inverse correlation was observed between albumin and both C-reactive protein and D-dimer at hospital admission (r = -.487 and r = -.479, respectively; P < .0001). Finally, a positive correlation was found between albumin levels and eGFR (r = .137; P = .049). Proteinuria was observed in 75% of patients with available data and it did not differ between patients with hypoalbuminemia and those with albumin ≥30 g/L (81% and 67%, respectively; P = .09). In patients with COVID-19, hypoalbuminemia is common and observed in quite an early stage of pulmonary disease. It is strictly associated with inflammation markers and clinical outcome. The common finding of proteinuria, even in the absence of creatinine increase, indicates protein loss as a possible biomarker of local and systemic inflammation worthwhile to evaluate disease severity in COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Hypoalbuminemia is frequently observed in patients with SARS-CoV-2 infection although its underlying mechanism and relationship with the clinical outcome still need to be clarified.
METHODS
METHODS
We retrospectively evaluated in patients with COVID-19 hospitalised at the Fatebenefratelli-Sacco Hospital in Milan, the prevalence of hypoalbuminemia, its association with the severity of COVID-19, with the levels of C-reactive protein, d-dimer and interleukin-6 and with clinical outcome over a follow-up period of 30 days. Urinalysis was evaluated in a subgroup of patients.
RESULTS
RESULTS
Serum albumin levels <30 g/L were found in 105/207 (50.7%) patients at hospital admission. Overall, the median albumin value was 29.5 g/L (IQR 25-32.8). A negative association was found between albumin levels and severity of COVID-19 (P < .0001) and death (P = .003). An inverse correlation was observed between albumin and both C-reactive protein and D-dimer at hospital admission (r = -.487 and r = -.479, respectively; P < .0001). Finally, a positive correlation was found between albumin levels and eGFR (r = .137; P = .049). Proteinuria was observed in 75% of patients with available data and it did not differ between patients with hypoalbuminemia and those with albumin ≥30 g/L (81% and 67%, respectively; P = .09).
CONCLUSION
CONCLUSIONS
In patients with COVID-19, hypoalbuminemia is common and observed in quite an early stage of pulmonary disease. It is strictly associated with inflammation markers and clinical outcome. The common finding of proteinuria, even in the absence of creatinine increase, indicates protein loss as a possible biomarker of local and systemic inflammation worthwhile to evaluate disease severity in COVID-19.
Identifiants
pubmed: 33332691
doi: 10.1111/ijcp.13946
pmc: PMC7883050
doi:
Substances chimiques
Serum Albumin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13946Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Int J Clin Pract. 2021 Apr;75(4):e13946
pubmed: 33332691
Austin J Vasc Med. 2015 Jun 4;2(1):
pubmed: 26973981
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Prog Cardiovasc Dis. 2010 May-Jun;52(6):493-9
pubmed: 20417342
J Infect. 2020 Apr;80(4):394-400
pubmed: 32109443
Eur Respir J. 2010 Feb;35(2):331-7
pubmed: 19741024
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Crit Care. 2015 May 11;19:225
pubmed: 25959381
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Clin Infect Dis. 2020 Jul 28;71(15):833-840
pubmed: 32296824
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Ann Intern Med. 2003 Jul 15;139(2):137-47
pubmed: 12859163